no weight loss semaglutide Or Tirzepatide: Which Injection Is Right For You? In adults with obesity but

Boundary This is not a dosing recommendation

Differential status of kidney function and changes in renal vascular resistance of the preglomerular arterioles may account for the different responses of the human study participants

More analysis here, with what Lilly's new approval means for both it and for the broader obesity marketplace (subscription required): To view or add a comment, sign in Now that Lilly has an approval for orforglipron (now Foundayo), everyone seems to be salivating to see how fast this drug can take off in the oral obesity space, and what it means for Novo Nordisk's oral Wegovy

Heavy or binge drinking should be avoided, especially during dose escalation